Edinburgh Molecular Imaging

Edinburgh Molecular Imaging develops fluorescent imaging systems based on molecular imaging technology for cancer detection and surgical guidance. The company focuses on the discovery and development of small molecules and peptides that, when conjugated with fluorescent dyes, target and specifically bind with cancerous cells and other diseased tissue. Its imaging platform is based on molecules with three components: a carrier backbone or pharmacokinetic modulator coupled to a targeting agent, with a linker to improve bioavailability, binding affinity, and stability. This approach enables real-time visualization of tumors and diseased tissue during surgical procedures, potentially improving surgical outcomes through more precise tumor identification and removal. Founded in 2014 and headquartered in Edinburgh, United Kingdom, the company has raised $10.7M in Series A funding from investors including Epidarex Capital, Scottish Enterprise, and Europa.